Could the Immune System Help Predict How a Cancer May Behave?
Could the immune system help doctors predict whether a cancer will grow, spread, or return after treatment? Research suggests that the answer is yes, at least for certain types of cancer. Scientists are discovering that immune cells found inside and around a tumor can provide valuable clues about how the disease may behave. These clues may help doctors estimate the risk of cancer recurrence and, in some situations, understand which treatments are more likely to work. However, immune activity is complicated, and a strong immune response does not always guarantee a better outcome. This article explains how the immune system interacts with cancer, what researchers have discovered, which tests are being studied, and what these findings could mean for patients.
How Does the Immune System Interact With Cancer?
The immune system helps protect your body by recognizing and responding to harmful organisms and abnormal cells. It can sometimes identify cancer cells and destroy them before they develop into larger tumors. However, some cancer cells find ways to avoid detection or interfere with the immune response.
This creates an ongoing interaction between cancer cells and the body's natural defenses.
How Does the Body Recognize Cancer Cells?
Healthy cells follow instructions that control when they grow, divide, and die. Cancer develops when changes in these instructions allow abnormal cells to multiply without normal control.
Some cancer cells produce unusual proteins that immune cells can recognize as potential warning signs.
One important group of immune cells is called T cells. These are white blood cells that help coordinate immune responses and, in some cases, directly destroy abnormal cells.
Certain T cells, known as CD8-positive or killer T cells, can recognize and attack cancer cells displaying specific abnormal proteins.
Other immune cells also participate in this process. Some help activate T cells, while others remove damaged cells or regulate inflammatio
Why Can Cancer Grow Despite the Immune System?
Cancer cells can develop mechanisms that make them harder for immune cells to recognize or attack.
For example, some tumors produce signals that reduce nearby immune-cell activity. Others create physical barriers that prevent immune cells from reaching cancer cells.
A tumor also contains more than cancer cells. It includes blood vessels, supporting tissues, chemical signals, and different types of immune cells.
Together, these surroundings are called the tumor microenvironment.
The National Cancer Institute's research on the tumor microenvironment explains how interactions between cancer cells, immune cells, and surrounding tissues can influence tumor growth, spread, and recurrence.
Understanding these interactions is important because two cancers that appear similar under a microscope may behave differently depending on what is happening around them.
How Can the Immune System Help Predict How a Cancer May Behave?
The immune system may help predict cancer behavior by revealing how strongly immune cells are responding to a tumor. Researchers examine the types of immune cells present, their numbers, and where they are located.
These patterns can sometimes help estimate the likelihood of cancer progression or recurrence. However, their meaning depends on the cancer type and cannot be interpreted in isolation.
Why Do Immune Cells Inside a Tumor Matter?
When researchers examine a cancer tissue sample, they may find immune cells that have moved into the tumor itself.
These cells are called tumor-infiltrating lymphocytes, or TILs.
Lymphocytes are white blood cells involved in immune defense. When they enter a tumor, their presence may suggest that the immune system has recognized something abnormal.
In certain cancers, especially when particular cancer-fighting T cells are present, greater immune-cell activity has been associated with more favorable outcomes.
However, the number of immune cells alone does not tell the whole story.
Researchers also need to know whether those cells are actively fighting the cancer, have become less effective, or are being prevented from reaching cancer cells.
Does the Location of Immune Cells Make a Difference?
Yes. Immune cells found deep inside a tumor may tell researchers something different from immune cells gathered only around its outer edge.
For example, a tumor may contain many immune cells nearby, but few may be able to enter the cancerous tissue.
This could suggest that the tumor has developed barriers that interfere with the immune response.
Researchers are therefore studying not only how many immune cells are present but also how they are arranged.
Immune-related features researchers study to understand cancer behavior.
Immune feature | What researchers examine | What it may suggest | Important limitation |
Cancer-fighting T cells | The number of specific T cells within a tumor | Higher levels may be linked with better outcomes in certain cancers | The association varies by cancer type |
Immune cells around the tumor | Whether immune cells remain at the outer edge | The tumor may be limiting immune-cell access | Location alone cannot predict progression |
Immune-suppressing cells | Cells that can reduce anticancer immune activity | The tumor may be creating conditions that support its survival | Some immune-cell types have multiple functions |
Organized immune-cell groups | Clusters of immune cells working together | May indicate a more coordinated immune response | Their clinical value is still being studied |
Immune-related proteins | Signals that activate or suppress immune responses | May help explain how cancer interacts with immunity | A single marker rarely gives a complete answer |
These findings are helping researchers understand cancer as more than a collection of abnormal cells.
The surrounding immune response may provide another useful layer of information when combined with established cancer tests.
What Is Immunoscore, and What Has Research Found?
Immunoscore is a test developed to measure particular immune cells inside and around colon tumors. Research has shown that it can provide useful information about the risk of cancer returning after surgery, especially in people with earlier-stage colon cancer.
Unlike tests that focus mainly on the cancer cells, Immunoscore evaluates part of the body's immune response to the tumor.
How Does Immunoscore Work?
The test examines tissue that has already been removed during cancer surgery.
Special laboratory methods identify two groups of immune cells:
CD3-positive T cells: A broad group of T cells involved in immune responses.
CD8-positive T cells: T cells that can directly attack abnormal cells, including certain cancer cells.
The laboratory measures the
No. Immunoscore is intended to provide additional information rather than replace established methods of assessing cancer.
Doctors still rely on features such as:
The location and type of cancer.
The size and extent of the tumor.
Whether cancer has reached nearby lymph nodes.
Whether it has spread to distant organs.
The appearance and biological characteristics of cancer cells.
Immunoscore has been studied most extensively in colon cancer. Its availability, clinical use, and importance in treatment decisions vary across healthcare systems.
Although some professional guidance recognizes its potential to refine prognosis, it is not a routine replacement for standard staging or a reason to change chemotherapy without an oncology team's assessment.
Can Immune Markers Predict Whether Cancer Treatment Will Work?
Some immune-related markers can help doctors estimate whether particular cancer treatments are likely to work, especially treatments that use the immune system to attack cancer.
However, predicting treatment response is different from predicting how cancer will behave without a particular treatment.
This distinction is important when interpreting test results.
What Is the Difference Between Prognostic and Predictive Markers?
A prognostic marker provides information about the likely course of a disease, such as the chance of cancer returning.
A predictive marker helps identify whether someone is more or less likely to benefit from a particular treatment.
For example, an immune-cell pattern associated with a lower risk of colon cancer recurrence is a prognostic finding.
A tumor characteristic suggesting that a person may benefit from a specific immunotherapy is a predictive finding.
Some biomarkers can provide both kinds of information, but that does not mean they can predict every outcome.
Which Immune-Related Tests Are Used in Cancer Care?
Several established biomarkers can help guide treatment decisions for selected cancers.
PD-L1 testing: PD-L1 is a protein that can help cancer cells suppress the immune response. Measuring it may help doctors decide whether certain immunotherapy medicines are appropriate.
Microsatellite instability (MSI) and mismatch repair (MMR) testing: These tests assess whether cancer cells have problems correcting mistakes in their DNA. Certain results can help identify tumors that may respond to particular immunotherapies.
Tumor mutational burden (TMB): This measures the number of genetic changes in cancer cells. In specific clinical situations, it may help estimate the likelihood of benefiting from certain immune-based treatments.
These tests do not all directly measure immune-cell numbers. Some instead examine tumor characteristics that influence how the immune system recognizes cancer.
The National Cancer Institute's guide to biomarker testing for cancer treatment explains how genetic and protein markers can help doctors select therapies and why a matching result does not guarantee treatment success.
Why Doesn't a Positive Biomarker Guarantee Treatment Success?
Cancer is complicated, and tumors can contain different groups of cells with different characteristics.
Even when a test suggests that immunotherapy may work, some cancer cells may resist treatment.
The immune cells surrounding the tumor may also be unable to respond effectively, or the cancer may change over time.
For this reason, doctors consider biomarker results alongside the cancer type, stage, previous treatments, general health, and established clinical evidence.
A positive marker may improve confidence in a treatment choice, but it cannot guarantee that the cancer will shrink or disappear.
What New Research Could Improve Cancer Predictions?
Researchers are investigating ways to combine immune-cell information with genetic tests, medical records, imaging, and advanced computer analysis. The goal is to create more reliable estimates of cancer behavior and treatment response.
These approaches may eventually help doctors identify important differences between tumors that currently appear similar.
Could Organized Groups of Immune Cells Provide New Clues?
Scientists have identified organized groups of immune cells within or near certain tumors.
These are called tertiary lymphoid structures, or TLS.
They resemble small immune-system gathering places, where different immune cells can communicate and coordinate their responses.
Studies suggest that their presence may be associated with better outcomes or a greater likelihood of responding to immunotherapy in some cancers.
For example, a systematic review and meta-analysis published in 2025 examined 15 studies involving 1,307 patients.
It found associations between higher levels of these immune structures and improved outcomes among patients receiving immunotherapy.
However, the included studies involved different cancers and testing methods. The results show promise but do not establish TLS measurement as a universal clinical test.
Researchers still need to determine which structures matter most, how to measure them consistently, and when the information should influence treatment.
Can Artificial Intelligence Help Analyze Immune-Related Patterns?
Artificial intelligence, or AI, can examine large amounts of medical information and identify patterns that may be difficult to recognize using simpler methods.
In cancer research, AI is being studied as a way to combine laboratory findings, tumor characteristics, and patient information.
One example is SCORPIO, a research tool developed to predict outcomes in people receiving a type of immunotherapy called immune checkpoint inhibitors.
The National Cancer Institute's report on AI-based immunotherapy prediction , published in February 2025, describes research using routine blood tests and patient records from nearly 10,000 people across the model's development and evaluation.
The tool showed promising accuracy in predicting survival and treatment response across several cancer types. However, SCORPIO is still being evaluated for broader clinical use and should not be treated as an established replacement for oncology assessment.
Importantly, this approach does not mean an ordinary blood test can reliably predict how any untreated cancer will behave. The model was developed in the context of patients receiving specific cancer treatments.
What Still Needs to Be Established?
Before an experimental immune marker becomes a routine clinical test, researchers need evidence that it provides accurate and useful information across different patient populations.
They also need to establish whether using the test to guide decisions actually improves patient care.
A marker can be associated with survival in a study without necessarily helping doctors choose a better treatment.
Researchers therefore need to assess:
Whether test results are consistent between laboratories.
Whether findings apply to different stages and types of cancer.
Whether the test improves predictions beyond existing methods.
Whether using the result changes treatment decisions safely.
Whether patients experience better outcomes when care is guided by the test.
These questions help separate interesting scientific discoveries from tests that are ready for everyday medical practice.
What Should Patients Know About Immune-Based Cancer Testing?
Immune-based cancer testing may provide useful information, but not every patient needs an additional immune test. The most important question is whether a particular test has been shown to help with decisions about your specific cancer.
Your oncology team can explain which tests are established, which are optional, and which are mainly used in research.
How Are These Tests Performed?
Some immune-related tests are performed on tumor tissue collected during a biopsy or surgery.
A pathologist, a doctor who examines tissues and cells to diagnose disease, may use special laboratory stains to identify particular proteins or immune cells.
Other tests examine DNA changes within the cancer.
Some newer research methods combine several kinds of information, including blood results and medical records.
Not every test requires a new biopsy. In certain situations, tissue already collected during diagnosis or surgery may be suitable for additional testing.
What Should You Ask Your Cancer Care Team?
If you are interested in immune-based cancer testing, a few focused questions may help you understand whether it applies to your care.
Useful dos and don'ts when discussing immune-based cancer tests.
Do | Don't | Why It Matters |
Ask whether a test is recommended for your cancer type | Assume every immune test applies to every cancer | Evidence differs between cancers |
Ask whether the result predicts recurrence or treatment response | Treat prognosis and treatment prediction as the same thing | The tests answer different questions |
Discuss results alongside cancer stage and other findings | Interpret one immune marker by itself | Cancer behavior depends on several factors |
Ask whether a test is established or experimental | Assume a published study makes a test standard care | Research findings need clinical validation |
Ask how the result might change your treatment plan | Request testing without understanding its purpose | Testing is most useful when results inform care |
Continue recommended treatment and follow-up | Change treatment because of an immune score alone | Unsupervised changes may affect cancer control |
Does a Healthy Lifestyle Change These Immune Scores?
A healthy lifestyle supports overall well-being, including normal immune function, but there is no established evidence that supplements, special diets, or attempts to "boost immunity" will reliably improve a tumor's Immunoscore or prevent cancer progression.
The immune-cell patterns measured inside tumors are not the same as a general assessment of how strong or weak someone's immune system is.
Balanced nutrition, appropriate physical activity, adequate rest, and avoiding tobacco can be important parts of supportive cancer care.
However, none should be treated as a substitute for evidence-based cancer treatment.
A tumor's immune environment may help reveal how a cancer is likely to behave, but no single immune marker tells the whole story. The greatest clinical value comes from combining validated immune findings with cancer stage, tumor biology, treatment history, and other established medical information.
When Should You Seek Medical Advice?
If you have been diagnosed with cancer, speak with your oncology team before requesting an experimental immune test or making treatment decisions based on research findings.
An unfavorable immune marker does not mean that treatment will fail. Similarly, a favorable result does not mean that follow-up care is unnecessary.
Contact your cancer care team promptly if you develop new or worsening symptoms, unexplained pain, unusual bleeding, or other changes they have advised you to report.
Seek urgent medical care for serious symptoms such as difficulty breathing, severe confusion, uncontrolled bleeding, or other sudden medical emergencies.
If you are receiving cancer treatment, report concerning side effects promptly rather than waiting for your next routine appointment.
Do not stop prescribed medicines, delay recommended treatment, or replace cancer care with products marketed as immune boosters.
The meaning of any immune-based test should be discussed with a qualified cancer specialist who understands your diagnosis and overall treatment plan.
Conclusion
The immune system could become an increasingly useful part of predicting how a cancer may behave. Studies of immune cells inside tumors, including research on Immunoscore in colon cancer, show that the body's response to cancer can provide meaningful information about recurrence risk. New approaches involving immune biomarkers and artificial intelligence may offer further insights, although many still require clinical validation.
These findings are promising, but they cannot predict an individual's future with certainty or replace established cancer assessments. If you or someone you care for has cancer, ask the oncology team which biomarker tests are relevant and how the results might influence treatment decisions.
Frequently Asked Questions
1. Can the immune system predict whether cancer will spread?
Certain immune-cell patterns may help estimate the risk of cancer progression or recurrence. However, they cannot reliably predict whether an individual cancer will spread. Doctors must also consider cancer type, stage, genetic features, treatment response, and other medical findings.
2. Does having more immune cells in a tumor mean a better prognosis?
Not always. Higher numbers of certain cancer-fighting T cells are associated with better outcomes in some cancers. However, different immune cells have different functions, and their location and activity matter. A higher immune-cell count alone cannot establish a favorable prognosis.
3. What is Immunoscore in cancer testing?
Immunoscore measures specific T cells inside and around colon tumors to help estimate the risk of recurrence. Research supports its prognostic value, particularly in earlier-stage colon cancer. It supplements other clinical findings and is not routinely appropriate for every cancer type.
4. Can a blood test show how aggressive a cancer is?
Some blood tests provide information about cancer activity, but no single routine blood test reliably measures aggressiveness across all cancers. Researchers are developing models that combine blood findings with clinical information. These tools require validation for specific uses before guiding treatment.
5. Can immune biomarkers predict whether immunotherapy will work?
Some biomarkers, including PD-L1, MSI or mismatch repair status, and tumor mutational burden, can help guide immunotherapy decisions in selected cancers. However, none guarantees a response. Their usefulness depends on the cancer type, treatment, and applicable clinical evidence.
6. Can boosting the immune system improve cancer prognosis?
There is no reliable evidence that general immune-boosting supplements or diets can change a tumor's immune score or cure cancer. Healthy habits can support overall health during treatment. Discuss any supplements or major lifestyle changes with your cancer care team.
Comments